Biotech Startups

Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases. The company combines proprietary chemistry, target biology, and predictive sciences to advance drug candidates for cancer and other therapeutic areas.

4 investors

Aperture Bio develops technologies to translate human tumor biology in order to reduce risk in preclinical drug development.

4 investors

Apollomics is a biotechnology company focused on discovering and developing oncology therapies designed to combine with other treatments, using approaches that engage the immune system and target specific molecular pathways to inhibit cancer. It operates as a publicly traded (Nasdaq-listed) drug developer with clinical programs including vebreltinib (APL-101).

4 investors

Applied Cognition develops neuroscience-based therapeutics and diagnostics, leveraging AI and deep expertise in drug development and clinical research for neurological disorders. The company combines scientific discovery with translational research and commercialization capabilities.

4 investors

Aptimmune develops vaccines for swine health, partnering with vaccine development and swine health consulting companies to speed product development, testing and manufacturing. It serves the swine veterinary and animal health industry.

4 investors

AqueSys was a clinical-stage ophthalmic device company behind the XEN Gel/XEN45 glaucoma shunt, acquired by Allergan in 2015.

4 investors

Arbutus Medical develops FDA-cleared surgical devices for orthopedic trauma procedures, including innovative drill technology and sterile-packed procedure kits designed for use in low-resource hospitals globally.

4 investors

ArcaScience provides AI-powered benefit-risk intelligence for pharmaceutical drug development, replacing manual literature reviews and CRO services to support decision-making from candidate selection through post-marketing surveillance. The platform serves pharmaceutical teams and regulatory bodies with compliance-ready analyses.

4 investors

Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs. It focuses on therapeutic areas including chronic kidney disease with hyperphosphatemia and irritable bowel syndrome with constipation.

4 investors

AreCor develops proprietary pharmaceutical products for diabetes, obesity, and cardiometabolic diseases using its Arestat technology platform. The company targets areas of high unmet patient need in high-value therapeutic markets.

4 investors

ArgenTag develops a single-cell RNA sequencing kit that converts mRNA from individual cells into barcoded cDNA for long-read sequencing on PacBio or Oxford Nanopore platforms. The benchtop workflow requires no specialized equipment, no capital instruments, and completes sample processing in five hours with minimal hands-on time.

4 investors

Ark applies machine learning and AI to bioprocessing, replacing trial-and-error methods with hybrid predictive models to accelerate drug development and scale biotherapeutic manufacturing. The platform serves biopharmaceutical companies and biotech firms seeking to reduce R&D timelines and production costs.

4 investors

ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies. It serves patients with allergies and their caregivers.

4 investors

ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue. The company covers the design, manufacture, and distribution of its therapies and builds on radiation research from the University of Oslo and Norway's Radium Hospital.

4 investors

Arthex Biotech develops antisense RNA compounds to treat diseases with unmet medical needs. The company focuses on microRNA-based therapeutic interventions.

4 investors

Arzeda designs proteins and metabolic pathways using computational tools, including its Archytas protein design software and Scylax metabolic pathway design software. The company operates in the computational biology and protein engineering field.

4 investors

Asgard Therapeutics develops direct cell reprogramming technologies that convert cancer cells into dendritic cells to restore anti-cancer immune responses. The company focuses on oncology immunotherapy through its TrojanDC approach.

4 investors

Astek Diagnostics develops a diagnostic platform for rapid and accurate detection of urinary tract infections and related conditions in clinical specimens. The company serves physicians and patients needing point-of-care diagnostic solutions for infectious diseases.

4 investors

Astrivax Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies to treat virus-driven cancers, particularly HPV16-associated cancers like cervical and head and neck cancer. The company's Launch-iT platform generates durable T-cell responses against virus-infected cells and is advancing toward clinical proof-of-concept.

4 investors

Atai Beckley develops rapid-acting, durable, and convenient therapies for mental health conditions where patients currently have limited treatment options. The company focuses on evidence-based drug development aimed at improving patient outcomes in mental health care.

4 investors

Atalanta is developing treatment options for intractable central nervous system diseases using RNA interference technology. The company was founded by leading experts in RNAi research.

4 investors

Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease. The company focuses on next-generation cell-based therapies designed for patients worldwide.

4 investors

Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology. The company is advancing multiple drug programs toward regulatory approval and clinical applications for patients with significant unmet medical needs.

4 investors

Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV). Its work spans antiviral drug discovery, medicinal chemistry, biology, and virology.

4 investors